icon-    folder.gif   Conference Reports for NATAP  
  22nd Conference on Retroviruses and
Opportunistic Infections
Seattle Washington Feb 23 - 26, 2015
Back grey_arrow_rt.gif
Statins Improve SVR, Reduce Fibrosis Progression and HCC Among HCV+ Persons. Statins Reduce Plaque/Halt Carotid Artery Wall Thickening/Improve Kidney
  Reported by Jules Levin
CROI 2015 Feb 23-26, seattle, WA
Adeel A. Butt1,2,3, Peng Yan1, Obaid S. Shaikh1,2, Shari S. Rogal1,2, for the ERCHIVES study team 1VA Pittsburgh Healthcare System, Pittsburgh, PA, USA; 2University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 3Hamad Medical Corporation, Doha, Qatar
from Jules: Statins were a key story out of CROI 2015 with these findings.... of note, this study finding on statin use in preventing cirrhosis & HCC & increasing SVR rate was conducted before DAA without peg interferon use. Still this study is of keen interest as well as these additional studies on statins at CROI 2015. Statins have an anti-inflammation/activation affect which may play an adjunctive role to DAA HCV cure. It might be helpful to conduct a study examining statin benefits to patients on HCV DAAs who attain a cure or not looking at long-term outcomes - cirrhosis etc may be useful.
CROI: Statin Therapy Reduces Coronary Noncalcified Plaque Volume in HIV-infected Patients: a Randomized Controlled Trial - (03/02/15)...... CROI: Atorvastatin for 1 year trims coronary artery plaque volume and number in placebo trial> - written by Mark Mascolini - (03/02/15)
CROI: Rosuvastatin halts carotid artery wall thickening in placebo-controlled trial - (02/27/15)
CROI: The Kidney at CROI 2015 - (03/06/15) ....Lene Ryom PhD, CHIP, Department of Infectious Diseases and Rheumatology, Section 2100, Rigshospitalet - University of Copenhagen, Denmark; Christina Wyatt MD, Associate Professor, Medicine/ Nephrology Icahn School of Medicine at Mount Sinai New York, NY
Lipids and lipid-lowering therapy: impact on the kidney: "A prospective cohort study of ART-naive adults initiating ART in South Africa demonstrated a significant association between elevated total cholesterol and risk of decreased kidney function (eGFR< 90) [Abstract 781]. In a small single-center study of rosuvastatin use among adults without conventional indications for statin therapy but with evidence of coronary artery plaque, eGFR was stable in participants randomized to the active treatment arm, in contrast to a small decline in the placebo arm [Abstract 136]. The differences did not reach statistical significance, but were consistent with observations in the SATURN trial. The impact of statins on kidney function should be evaluated in larger studies with adequate power to detect a clinically meaningful effect."